

The cancer immunotherapy market is primed for growth, with Immune Checkpoint Inhibitors, otherwise known as Immune Checkpoint Modulators, representing one of the area's newest and most promising treatments.

This buzz of attention has propelled the R&D race in the immune checkpoint modulator arena, which boasts an optimistic pipeline of therapies with all eyes set on obtaining blockbuster status.


Pharma IQ presents this immune checkpoint modulator venture map, providing an overview of various companies developing products in the space and the cancers of focus. In cases where information could not be gathered on a modulator's specific cancer of focus, the term 'variety of tumors' was chosen.

Move your mouse over the icons on the body to see which companies are interested in that cancer of focus.

**General - Solid Tumors** 



## Interactive Immune Checkpoint Modulator Venture Map



## Immune Checkpoint Modulation & Combination Therapies 2016

Focusing on the challenges of developing checkpoint modulators, taking them from pre-clinical to clinical stages and getting drugs to market, Pharma IQ's Immune Checkpoint Modulation and Combination Therapies conference is a can't-miss event for anyone working in, or looking to work in this space.



Visit http: www.immunecheckpointmodulation.com/

Number: **+44 (0)207 036 1300** Email: **enquire@igpc.co.uk** 

**Download the agenda**